Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

PBI-4050 Reduces Stellate Cell Activation and Liver Fibrosis through Modulation of Intracellular ATP Levels and the Liver Kinase B1/AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway.

Grouix B, Sarra-Bournet F, Leduc M, Simard JC, Hince K, Geerts L, Blais A, Gervais L, Laverdure A, Felton A, Richard J, Ouboudinar J, Gagnon W, Leblond FA, Laurin P, Gagnon L.

J Pharmacol Exp Ther. 2018 Oct;367(1):71-81. doi: 10.1124/jpet.118.250068. Epub 2018 Aug 9.

PMID:
30093459
2.

Nonadherence with inhaled preventer therapy in severe asthmatic patients on long-term omalizumab.

Allen DJ, Holmes LJ, Hince KA, Daly R, Ustabashi C, Tavernier G.

Eur Respir J. 2018 Aug 16;52(2). pii: 1801025. doi: 10.1183/13993003.01025-2018. Print 2018 Aug. No abstract available.

PMID:
29976649
3.

A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors: GPR40 and GPR84.

Gagnon L, Leduc M, Thibodeau JF, Zhang MZ, Grouix B, Sarra-Bournet F, Gagnon W, Hince K, Tremblay M, Geerts L, Kennedy CRJ, H├ębert RL, Gutsol A, Holterman CE, Kamto E, Gervais L, Ouboudinar J, Richard J, Felton A, Laverdure A, Simard JC, L├ętourneau S, Cloutier MP, Leblond FA, Abbott SD, Penney C, Duceppe JS, Zacharie B, Dupuis J, Calderone A, Nguyen QT, Harris RC, Laurin P.

Am J Pathol. 2018 May;188(5):1132-1148. doi: 10.1016/j.ajpath.2018.01.009. Epub 2018 Feb 16.

Supplemental Content

Support Center